Motor Neurone Disease Trial, Recruiting NCT06877143 Sponsor: University of Ulm Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06877143
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ALS (also known as Lou Gehrig's disease), either as a possible, probable, or confirmed case, based on recognised international diagnostic guidelines
  • Your ALS symptoms have been progressing at a certain rate since they first began — this is calculated using your score on a standard ALS function questionnaire at your screening visit (confirm with trial site for exact calculation)
  • You are currently receiving nutrition through a feeding tube placed directly into the stomach (called a PEG tube)
  • You are 18 years of age or older
  • You have either been taking a stable dose of the medication riluzole for at least 4 weeks, or you are not taking riluzole at all
  • You are able to fully understand the information given about the trial and are able to give your informed consent to participate

Who may not be able to join:

  • You have taken part in another clinical trial involving a treatment or intervention within the last 4 weeks
  • You do not have enough social support around you, or the investigator feels you may not be able to complete the study for personal or practical reasons
  • You are currently pregnant or breastfeeding
  • You have a significant psychiatric condition or signs of notable memory or thinking difficulties (such as dementia)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christine Herrmann, Dr., University of Ulm

Phone: 0049 731 177 5374

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Ulm
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 March 2031

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Neurofilament light chain (NfL) in serum

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov